1-5mm与6-9mm腺瘤对异时性进展期结直肠肿瘤风险的比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项研究共36,142例患者,比较不同大小和数量的非进展期腺瘤患者异时性进展期结直肠肿瘤(ACRN)风险。结果显示,≤2个小腺瘤(6-9mm)患者风险高于≤2个微小腺瘤(1-5mm)患者(RR 1.49),≥3个小腺瘤和进展期腺瘤患者风险均高于≥3个微小腺瘤患者(HR分别为1.51和1.92),而≥3个微小腺瘤与≤2个小腺瘤之间无显著差异。作者认为指南应考虑仅对微小腺瘤患者延长监测间隔。
要点
- ≤2个小腺瘤(6-9mm)患者异时性ACRN风险是≤2个微小腺瘤(1-5mm)的1.49倍
- ≥3个小腺瘤和进展期腺瘤患者风险分别高于≥3个微小腺瘤(HR 1.51和1.92)
- ≥3个微小腺瘤与≤2个小腺瘤之间ACRN风险无显著差异(HR 1.23)
核心结论
- 在低风险和高风险腺瘤组中,仅有微小非进展期腺瘤(1-5mm)的患者异时性ACRN风险低于有小腺瘤(6-9mm)者。
- 作者建议临床指南应考虑仅对微小非进展期腺瘤患者延长监测间隔。
研究设计与样本
- 系统综述与荟萃分析,检索截至2019年9月发表的相关研究。
- 共纳入8项研究,涉及36,142例患者。
- 低风险腺瘤(LRA)分为LRA-1(≤2个微小非进展期腺瘤)和LRA-2(≤2个小非进展期腺瘤)。
- 高风险腺瘤(HRA)分为HRA-1(≥3个微小非进展期腺瘤)、HRA-2(≥3个小非进展期腺瘤)和HRA-3(进展期腺瘤)。
主要发现
- LRA-2组异时性ACRN风险高于LRA-1组(风险比1.49;95%CI 1.23-1.81)。
- HRA-2和HRA-3组异时性ACRN风险均高于HRA-1组(风险比分别为1.51 [95%CI 1.002-2.28] 和1.92 [95%CI 1.11-3.33])。
临床怎么用
- 对于仅有微小非进展期腺瘤(1-5mm)的患者,可考虑延长监测间隔。
- 对于有小腺瘤(6-9mm)的患者,即使数量≤2个,也应维持较短的监测间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The current guidelines recommend the same surveillance interval for ≥3 nonadvanced adenomas (NAAs), without discriminating between diminutive (1-5 mm) and small (6-9 mm) adenomas. Additionally, the same surveillance interval is recommended for patients with ≤2 diminutive NAAs and those with ≤2 small NAAs. However, it is questionable whether these recommendations are appropriate. METHODS: We searched all relevant studies published through September 2019 that examined the risk of metachronous advanced colorectal neoplasia (ACRN) according to the size (diminutive vs small) and the number of adenomas found during an index colonoscopy. Low-risk adenomas (LRAs) were subclassified into 2 categories (LRA-1, ≤2 diminutive NAAs; and LRA-2, ≤2 small NAAs), and high-risk adenomas (HRAs) were subclassified into 3 categories (HRA-1, ≥3 diminutive NAAs; HRA-2, ≥3 small NAAs; and HRA-3, advanced adenoma). RESULTS: Eight studies involving 36,142 patients were evaluated. The LRA-2 group had a higher risk of metachronous ACRN than the LRA-1 group (risk ratio, 1.49; 95% confidence interval [CI], 1.23-1.81). Additionally, the HRA-2 and HRA-3 groups had a higher risk of metachronous ACRN than the HRA-1 group (hazard ratios [HRs], 1.51 [95% CI, 1.002-2.28] and 1.92 [95% CI, 1.11-3.33], respectively). However, there was no significant difference between the HRA-1 versus LRA-2 groups (HR, 1.23; 95% CI, .78-1.94). CONCLUSIONS: Among the HRA and LRA groups, those with diminutive NAAs had a lower risk of metachronous ACRN than those with small NAAs. We believe that clinical guidelines should consider extending the surveillance intervals in patients with diminutive NAAs only.
引用
- Jung YS, Kim TJ, Nam E, et al. Comparative systematic review and meta-analysis of 1- to 5-mm versus 6- to 9-mm adenomas on the risk of metachronous advanced colorectal neoplasia. Gastrointest Endosc. 2020. PMID: 32334021. doi:10.1016/j.gie.2020.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。